Investor Presentaiton

1H 2021 performance Strong revenue growth and operating leverage KEUR H12021 H12020 Change Revenue 135,136 87,808 53.9% Custom Projects 76,207 33,504 127.5% Contract Manufacturing 45,765 42,901 6.7% Generics & Cosmetics 13,164 11,403 15.4% EBITDA 39,889 18,519 115.4% Adjusted EBITDA 43,240 18,519 133.5% Adjusted EBITDA in % of revenue 32.0% 21.1% 10.9 ppts Operating result (EBIT) 30,803 10,160 203.2% Operating result (EBIT) in % of revenue 22.8% 11.6% 11.2 ppts Result for the period 24,623 7.831 214.4% Result for the period in % of revenue 18.2% 8.9% 9.3 ppts Earnings per share (EUR), basic 0.79 0.26 Return on net operating assets (RONOA) 25.6% 12.2% 203.6% 13.4 ppts Cash and cash equivalents (end of period) Net cash flow from operating activities 187,362 41,038 8,727 13,949 Capital expenditures 24,989 Capital expenditures in % of revenue 18.5% 9,465 10.8% Total assets (end of period) 571,950 313,888 194.2% 164.0% 7.7 ppts 82.2% 1 Adjusted EBITDA excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic. Equity ratio (end of period) 67.4% 50.0% Employees (# of FTEs, average) 1,026 896 14.5% 17.4 ppts This table includes references to alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group's consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, refer to the section "Definitions and reconciliations" in PolyPeptide Group AG's half-year report 2021. GLOBAL SUPPORT FOR A QUALITY SOLUTION 17 PolyPeptide GROUP

View entire presentation